<DOC>
	<DOC>NCT01732939</DOC>
	<brief_summary>The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.</brief_summary>
	<brief_title>Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer</brief_title>
	<detailed_description>The investigators hope to get preliminary results for the breast cancer patients who are given different neoadjuvant chemothetapy regimens. The patients are randomized two chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for 3-4 cycles.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosis of invasive ductal or lobular breast cancer. Previously untreated (no chemotherapy or hormonal therapy or radiation therapy) invasive breast cancer. no antiHer2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive) Performance Status ECOG &lt;2 Age &gt; 18 years Tumor &gt; 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky &gt;50% Lab test : Absolute neutrophil count &gt; 1,500/mm3 Total Bilirubin ≤ 2×ULN AST and ALT ≤ 2.5×ULN serum creatinine ≤ 1.5×ULN Pregnant or breast feeding patients are excluded stage Ⅳ breast cancer History of nonbreast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin uncontrolled cardiac disease Active infection or chronic infection requiring chronic suppressive antibiotics History of hypersensitivity reaction to investigating drugs</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>